UK markets close in 7 hours 20 minutes

Orion Oyj (0M2N.L)

LSE - LSE Delayed price. Currency in EUR
Add to watchlist
35.30+0.40 (+1.15%)
As of 04:04PM GMT. Market open.

Orion Oyj

Orionintie 1A
Espoo 02200
Finland
358 10 4261
https://www.orion.fi

Sector(s)
Industry
Full-time employees3,339

Key executives

NameTitlePayExercisedYear born
Mr. Timo LappalainenCEO, Pres & Chairman of the Exec. Management Board1.54MN/A1962
Mr. Jari Karlson M.Sc., M.Sc. (Econ.)CFO, Sr. VP of Animal Health & Member of the Exec. Management BoardN/AN/A1961
Mr. Olli HuotariSr. VP of Corp. Functions, Gen. Counsel, Sec. & Member of Exec. Management BoardN/AN/A1966
Ms. Satu AhomäkiSr. VP of Commercial Ops, Global Sales & Proprietary Products and Member of the Exe. Mgmt. BoardN/AN/A1966
Dr. Liisa HurmeSr. VP of Supply Chain & Member of the Exec. Management BoardN/AN/A1967
Ms. Virve LaitinenSr. VP of Specialty Products & Member of Exec. Management BoardN/AN/A1972
Prof. Outi Vaarala M.D., Ph.D.Sr. VP for R&D and Member of Exec. Management BoardN/AN/A1962
Mr. Tuukka Hirvonen M.Sc.(Soc.)Investor Relations & Financial Communications OfficerN/AN/AN/A
Ms. Terhi OrmioVP of CommunicationsN/AN/AN/A
Prof. Heikki Joensuu M.D., Ph.D.R&D Global Head of Therapy Area OncologyN/AN/AN/A
Amounts are as of 31 December 2020, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.

Description

Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, other European countries, North America, and internationally. It provides prescription drugs and self-care products, including Nubeqa for the treatment of prostate cancer; dexdor and Precedex for intensive care sedative; Stalevo and Comtess/Comtan for Parkinson's disease; Simdax for acute decompensated heart failure; and Fareston for breast cancer, as well as Salmeterol/fluticasone Easyhaler, Budesonide/formoterol Easyhaler, Formoterol Easyhaler, Budesonide Easyhaler, Beclomet Easyhaler, and Buventol Easyhaler for the treatment of asthma and chronic obstructive pulmonary disease. The company also offers veterinary drugs; and APIs for generic and proprietary drugs, as well as provides contract manufacturing services. In addition, it markets and sells veterinary drugs manufactured by other international companies. The company has a collaboration with Nanoform to apply Nanoform's CESS technology to new chemical entities. It serves various healthcare service providers and professionals, such as specialist and general practitioners, veterinarians, pharmacies, hospitals, healthcare centers, clinics, and laboratories. Orion Oyj has partnership with Propeller Health to connect the Easyhaler(R) line of inhalers for asthma and COPD to Propeller's digital medicine platform; and a research collaboration and license agreement with Alligator Bioscience AB (publ) to discover and develop new bispecific antibody cancer therapeutics. Orion Oyj is headquartered in Espoo, Finland.

Corporate governance

Orion Oyj’s ISS governance QualityScore as of 26 September 2021 is 8. The pillar scores are Audit: 3; Board: 2; Shareholder rights: 10; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.